This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Bio Pharma Dive
AUGUST 3, 2020
Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.
337 
Bio Pharma Dive
JANUARY 20, 2021
Results from a clinical trial in nursing home residents and staff offered the first evidence Lilly's bamlanivimab could protect against, as well as treat, COVID-19
281 This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
JANUARY 21, 2021
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
105 
NY Times
JANUARY 21, 2021
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
98 
pharmaphorum
OCTOBER 27, 2020
According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to help hospitalised patients recover from advanced-stage COVID-19. The post NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial appeared first on.
105 
pharmaphorum
OCTOBER 28, 2020
The US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million if the drug gets Emergency Use Authorisation (EUA) – although its effectiveness has been called into question. Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live.
96 
The Pharma Data
JANUARY 21, 2021
Eli Lilly reported yesterday that its monoclonal antibody bamlanivimab (LY-CoV555) significantly lessened the risk of contracting COVID-19 among nursing home residents and staff, according to findings from a phase 3 trial. James Miessler. Source link.
52 
The Pharma Data
NOVEMBER 26, 2020
26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. CHICAGO , Nov.
52 
The Pharma Data
JANUARY 12, 2021
million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.
52 
The Pharma Data
DECEMBER 29, 2020
First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).
52 
The Pharma Data
DECEMBER 17, 2020
NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.
52 
pharmaphorum
AUGUST 7, 2020
Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by year-end. Gillead lost $3.3bn in Q2, with the company blaming COVID-19 and its acquisition of immune-oncology company Forty Seven for the fall.
104 
pharmaphorum
DECEMBER 23, 2022
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Side effects and cost implications. Oral therapy data presented at ASH. CellCentric, a U.K-based
52 
The Pharma Data
SEPTEMBER 7, 2021
Volunteers for the trial are being enrolled at Columbia University in New York City and Clinilabs Drug Development Corporation, based in Eatontown, New Jersey. The vaccine currently being tested stimulates the body’s immune system to produce antibodies to oxycodone. The study plans to enroll up to 45 volunteers.
XTalks
JANUARY 8, 2024
Calliditas Therapeutics AB announced that the US Food and Drug Administration (FDA) has granted full approval for Tarpeyo (budesonide) delayed-release capsules, aimed at diminishing kidney function loss in adults diagnosed with primary immunoglobulin A nephropathy (IgAN) who are susceptible to disease advancement. mL/min/1.73 mL/min/1.73
64 
pharmaphorum
AUGUST 3, 2020
While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. Lilly and AbCellera intend to test the drug both for prophylaxis against the coronavirus and as a treatment for confirmed infections.
59 
The Pharma Data
JANUARY 22, 2021
Antibody Drug May Protect Nursing Home Residents, Staff From COVID-19. 22, 2021 — An antibody drug that has emergency use authorization from the U.S. Some received the drug and others were given a placebo. Professional. FRIDAY, Jan. The study included 299 residents and 666 staff.
52 
The Pharma Data
OCTOBER 18, 2020
Food and Drug Administration (FDA) for their at Home COVID-19 Nasal PCR Test. Since then, Eurofins has rolled out several highly sensitive and specific assays to thousands of clients nationwide, including hospitals, physicians’ offices, nursing homes, government entities, sports organizations and employers. Source link.
52 
pharmaphorum
JUNE 15, 2021
Antibody flunks post-exposure prevention study. Eli Lilly meanwhile reported positive results with its bamlanivimab antibody in the BLAZE-2 study carried put in nursing homes, which found a 57% reduction in the risk of infection compared to placebo.
119 
The Pharma Data
MARCH 20, 2023
(Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab (generic name, U.S. Food and Drug Administration (FDA) on January 6, 2023. productivity loss and informal care costs). In the U.S.,
40 
The Pharma Data
NOVEMBER 6, 2020
Finally, Dr. Balmuri and colleagues included the rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody status from patients’ diagnostic lab results as indicators of disease severity. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices.
52 
XTalks
JANUARY 5, 2021
Both drug discovery and drug repurposing to manage and treat the disease will also continue as experts learn more about the virology and epidemiology of the novel SARS-CoV-2 coronavirus that wreaked havoc in 2020. These include monoclonal antibody drugs, which are attractive therapeutic agents owing to their targeted specificity.
98 
pharmaphorum
FEBRUARY 10, 2021
The FDA has granted an emergency licence for Eli Lilly’s COVID-19 antibody combination therapy, to reduce chances of high-risk patients progressing from mild to moderate disease to more severe symptoms that may need hospital treatment. There are a range of other antibody therapies in various stages of development.
84 
The Pharma Data
DECEMBER 3, 2020
Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”. Food and Drug Administration (FDA), European Medicines Agency (EMA) or any other regulatory authorities. Complement-fixing antibodies against cytomegalovirus in different parts of the world. TAK-620 303 Memorandum.
52 
The Pharma Data
NOVEMBER 20, 2020
NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). TARRYTOWN, N.Y.,
52 
Bioengineer
JULY 23, 2021
The LOTIS-2 trial tested the efficacy of Loncastuximab tesirine, an antibody-drug complex that targets CD19 – the same molecule targeted on the lymphoma B-cells by CAR-T therapy. Once internalized, the drug damages the DNA of the lymphoma cells, leading to cell death.
52 
The Pharma Data
NOVEMBER 4, 2020
It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly. adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly.
52 
The Pharma Data
JANUARY 26, 2021
. “These exciting results, which replicate positive Phase 2 data in a much larger set of patients, add valuable clinical evidence about the role neutralizing antibodies can play in fighting this pandemic. Lilly’s chief scientific officer and president of Lilly Research Laboratories. have reached record highs.
52 
The Pharma Data
NOVEMBER 21, 2020
NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Regeneron Pharmaceuticals, Inc.
40 
The Pharma Data
JANUARY 26, 2021
Vir Biotechnology , Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir’s investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19. Food and Drug Administration to treat mild-to-moderate COVID-19 patients.
52 
XTalks
AUGUST 30, 2022
According to an analysis of the 2013 Medical Expenditure Panel Survey, one in six US adults reported taking a psychiatric drug at least once in 2013. CNS drugs treat a range of neurologic and psychiatric disorders, such as psychosis, depression, Parkinson’s disease, multiple sclerosis and epilepsy.
83 
The Pharma Data
NOVEMBER 5, 2020
The trial is supported by a grant to the University of Oxford from UK Research and Innovation / National Institute for Health Research (NIHR) and by core funding provided by NIHR Oxford Biomedical Research Centre , Wellcome , the Bill and Melinda Gates Foundation , the Department for International Development , Health Data Research UK , the (..)
52 
The Pharma Data
NOVEMBER 18, 2020
Eli Lilly and Company’s antibody therapeutic will be distributed as part of the federal government’s Operation Warp Speed. . 18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. TAMPA, Fla., Have chronic kidney disease.
40 
Pfizer
JANUARY 27, 2023
This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. Report vaccine side effects to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS).
112 
pharmaphorum
JANUARY 24, 2022
The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with COVID-19, extending the uses of the drug. ” It would have to be delivered as a daily intravenous infusion in these outpatient setting over three days.
95 
The Pharma Data
APRIL 8, 2021
Roche will present data on the increased use of home nursing capabilities in the Phase III GRADUATE studies of gantenerumab during the COVID-19 pandemic, which enabled home-bound trial participants to continue dosing to maintain medicine exposure. P1: Aging and Dementia: Biomarkers. Gantenerumab for Alzheimer’s Disease.
The Pharma Data
JANUARY 24, 2021
The drug appears to inhibit IL-6, IL-1beta, TNF-alpha and other pro-inflammatory cytokines and chemokines. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. Non-COVID-19-Related.
52 
The Pharma Data
MAY 27, 2022
Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival. 6],[7] The cilta-cel CAR protein features two BCMA-targeting single domain antibodies designed to confer high avidity against human BCMA.[1]
52 
XTalks
FEBRUARY 13, 2023
Radiopharmaceutical therapy (RPT) uses isotopes that are conjugated to tumor-targeting agents (such as peptides, antibodies and novel small molecules). Radionuclide-ligand conjugates, including radionuclides that are conjugated to antibodies or peptides, have been studied extensively. How does Radiopharmaceutical Therapy Work?
The Pharma Data
JUNE 18, 2021
The BTK protein sends important signals that tell B cells to mature and produce antibodies. This designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases. You are encouraged to report side effects of prescription drug to the FDA.
40 
The Pharma Data
JUNE 18, 2021
The BTK protein sends important signals that tell B cells to mature and produce antibodies. This designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases. You are encouraged to report side effects of prescription drug to the FDA. Drug Interactions.
52 
The Pharma Data
AUGUST 3, 2021
Food & Drug Administration (FDA) for Istodax ® (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. DRUG INTERACTIONS. About Istodax. 4 laboratory abnormalities (?10%) Source link: [link].
52 
The Pharma Data
AUGUST 11, 2020
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1 receptor blocking antibody or YERVOY. Consider the benefit versus risks of treatment with a PD-1 receptor blocking antibody or YERVOY prior to or after an allogeneic HSCT.
52 
The Pharma Data
AUGUST 11, 2020
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1 receptor blocking antibody or YERVOY. Consider the benefit versus risks of treatment with a PD-1 receptor blocking antibody or YERVOY prior to or after an allogeneic HSCT.
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content